ACS Medicinal Chemistry Letters
LETTER
(2) Grunnet, L. G.; Aikin, R.; Tonnesen, M. F.; Paraskevas, S.;
Blaabjerg, L.; Storling, J.; Rosenberg, L.; Billestrup, N.; Maysinger, D.;
Mandrup-Poulsen, T. Proinflammatory cytokines activate the intrinsic
apoptotic pathway in beta-cells. Diabetes 2009, 58, 1807–1815.
(3) Kim, E. K.; Kwon, K. B.; Song, M. Y.; Han, M. J.; Lee, J. H.; Lee,
Y. R.; Ryu, D. G.; Park, B. H.; Park, J. W. Flavonoids protect against
cytokine-induced pancreatic beta-cell damage through suppression of
nuclear factor kappaB activation. Pancreas 2007, 35, e1–e9.
(4) Matsuda, T.; Ferreri, K.; Todorov, I.; Kuroda, Y.; Smith, C. V.;
Kandeel, F.; Mullen, Y. Silymarin protects pancreatic beta-cells against
cytokine-mediated toxicity: Implication of c-Jun NH2-terminal kinase
and janus kinase/signal transducer and activator of transcription path-
ways. Endocrinology 2005, 146, 175–185.
(22) Marcaurelle, L. A.; Comer, E.; Dandapani, S.; Duvall, J. R.;
Gerard, B.; Kesavan, S.; Lee, M. D., IV; Liu, H.; Lowe, J. T.; Marie, J.-C.;
Mulrooney, C. A.; Pandya, B. A.; Rowley, A.; Ryba, T. D.; Suh, B.-C.;
Wei, J.; Young, D. W.; Akella, L. B.; Ross, N. T.; Zhang, Y. L.; Fass, D. M.;
Reis, S. A.; Zhao, W. N.; Haggarty, S. J.; Palmer, M.; Foley, M. A. An
aldol-based build/couple/pair strategy for the synthesis of medium- and
large-sized rings: Discovery of macrocyclic histone deacetylase inhibi-
tors. J. Am. Chem. Soc. 2010, 132, 16962–16976.
(23) Merglen, A.; Theander, S.; Rubi, B.; Chaffard, G.; Wollheim,
C. B.; Maechler, P. Glucose sensitivity and metabolism-secretion
coupling studied during two-year continuous culture in INS-1E insuli-
noma cells. Endocrinology 2004, 145, 667–678.
(24) This compound has been registered with NIH Molecular
Libraries Program (probe ML187) and is available upon request.
(25) Darville, M. I.; Eizirik, D. L. Regulation by cytokines of the
inducible nitric oxide synthase promoter in insulin-producing cells.
Diabetologia 1998, 41, 1101–1108.
(5) Larsen, L.; Tonnesen, M.; Ronn, S. G.; Storling, J.; Jorgensen, S.;
Mascagni, P.; Dinarello, C. A.; Billestrup, N.; Mandrup-Poulsen, T.
Inhibition of histone deacetylases prevents cytokine-induced toxicity in
beta cells. Diabetologia 2007, 50, 779–789.
(6) Lewis, E. C.; Blaabjerg, L.; Storling, J.; Ronn, S. G.; Mascagni, P.;
Dinarello, C. A.; Mandrup-Poulsen, T. The oral histone deacetylase
inhibitor ITF2357 reduces cytokines and protects islet beta-cells in vivo
and in vitro. Mol. Med. 2011, 17, 369–377.
(7) Chou, D. H.; Bodycombe, N. E.; Carrinski, H. A.; Lewis, T. A.;
Clemons, P. A.; Schreiber, S. L.; Wagner, B. K. Small-molecule sup-
pressors of cytokine-induced beta-cell apoptosis. ACS Chem. Biol. 2010,
5, 729–734.
(8) Burke, M. D.; Schreiber, S. L. A planning strategy for diversity-
oriented synthesis. Angew. Chem., Int. Ed. 2004, 43, 46–58.
(9) Schreiber, S. L. Target-oriented and diversity-oriented organic
synthesis in drug discovery. Science 2000, 287, 1964–1969.
(10) Nielsen, T. E.; Schreiber, S. L. Towards the optimal screening
collection: A synthesis strategy. Angew. Chem., Int. Ed. 2008, 47, 48–56.
(11) Bauer, R. A.; Wurst, J. M.; Tan, D. S. Expanding the range of
'druggable' targets with natural product-based libraries: an academic
perspective. Curr. Opin. Chem. Biol. 2010, 14, 308–314.
(12) Goess, B. C.; Hannoush, R. N.; Chan, L. K.; Kirchhausen, T.;
Shair, M. D. Synthesis of a 10,000-membered library of molecules
resembling carpanone and discovery of vesicular traffic inhibitors.
J. Am. Chem. Soc. 2006, 128, 5391–5403.
(13) Hubel, K.; Lessmann, T.; Waldmann, H. Chemical biology—
Identification of small molecule modulators of cellular activity by natural
product inspired synthesis. Chem. Soc. Rev. 2008, 37, 1361–1374.
(14) Koch, M. A.; Schuffenhauer, A.; Scheck, M.; Wetzel, S.;
Casaulta, M.; Odermatt, A.; Ertl, P.; Waldmann, H. Charting biologically
relevant chemical space: A structural classification of natural products
(SCONP). Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17272–17277.
(15) Marcaurelle, L. A.; Johannes, C.; Yohannes, D.; Tillotson, B. P.;
Mann, D. Diversity-oriented synthesis of a cytisine-inspired pyridone
library leading to the discovery of novel inhibitors of Bcl-2. Bioorg. Med.
Chem. Lett. 2009, 19, 2500–2503.
(16) Marcaurelle, L. A.; Johannes, C. W. Application of natural
product-inspired diversity-oriented synthesis to drug discovery. Prog.
Drug Res. 2008, 66, 189–216.
(17) Pelish, H. E.; Westwood, N. J.; Feng, Y.; Kirchhausen, T.;
Shair, M. D. Use of biomimetic diversity-oriented synthesis to
discover galanthamine-like molecules with biological properties
beyond those of the natural product. J. Am. Chem. Soc. 2001, 123,
6740–6741.
(18) Dandapani, S.; Marcaurelle, L. A. Accessing new chemical space
for 'undruggable' targets. Nat. Chem. Biol. 2010, 6, 861–863.
(19) Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland:
Increasing saturation as an approach to improving clinical success.
J. Med. Chem. 2009, 52, 6752–6756.
(20) Comer, E.; Liu, H.; Joliton, A.; Clabaut, A.; Johnson, C.; Akella,
L. B.; Marcaurelle, L. A. Fragment-based domain shuffling approach for
the synthesis of pyran based macrocycles. Proc. Natl. Acad. Sci. U.S.A.
2011, 108, 6751À6756.
(21) Gerard, B.; Duvall, J. R.; Lowe, J. T.; Murillo, T.; Wei, J.; Akella,
L. B.; Marcaurelle, L. A. ACS Comb. Sci. 2011, DOI: 10.1021/co2000218.
702
dx.doi.org/10.1021/ml200120m |ACS Med. Chem. Lett. 2011, 2, 698–702